Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Rate ePoster

Comprehensive Otolaryngology

(161) Effect of Short-chain Fatty Acids on Head and Neck Cancer

Monday, October 2, 2023
2:45 PM – 3:45 PM East Coast USA Time

    Presenting Author(s)

  • Masakazu Murayama, MD

    Ph. D. student
    Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University.
    Shinagawa-ku, Tokyo, Japan

    • Co-Author(s)

  • AK

    Atsuo Kuramasu, Prof.

    Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University., USA

  • SK

    Sei Kobayashi, Prof.

    Associate professor
    Department of Otorhinolaryngology, Showa university Fujigaoka Hospital.
    Yokohama, Kanagawa, Japan

  • TS

    Toshikazu Shimane, Prof.

    Head and Neck Oncology Center, Showa University., USA

  • HK

    Hitome Kobayashi, Prof.

    Department of Otorhinolaryngology - Head and Neck Surgery, Showa University School of Medicine., USA

  • YK

    Yuji Kiuchi, Prof.

    Department of Pharmacology, Showa University School of Medicine., USA

    • Senior Author(s)

  • KY

    Kiyoshi Yoshimura, Prof.

    Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University., USA

Disclosure(s):
Masakazu Murayama, MD: No relevant relationships to disclose.
Sei Kobayashi, Prof.: No relevant relationships to disclose.


Introduction: Recently, approaches to the tumor microenvironment, especially to intestinal bacteria, have been considered important to improve the response rate of cancer therapy. In this study, we focused on short-chain fatty acids-A (SCFA-A) as a metabolite of intestinal bacteria, and clarify the effects of SCFA-A on immune activity and tumor growth.

Methods: Human T3M-1 Cl-10 oral cancer cells and human T cells from healthy volunteers were co-cultured. They were treated with SCFA-A for 72 h. The changes in proliferation of human cancer cells and T cells were analyzed using flow cytometry. And gene expression and phenotype of T cells were also analyzed by qPCR and flow cytometry. SCFA-A was administered to macrophages derived from mouse bone marrow cells, and gene expression and phenotype of the macrophages were analyzed by qPCR and flow cytometry.

Results: SCFA-A inhibited tumor cell growth, but not T cells. The frequency of Ki67, ICOS, and PD-1 expression in T cells and gene expression of IFNG, ICOS, and PDCD1 in T cells were increased. The population of regulatory T cells and the frequency of Foxp3 expressing in T cells were decreased. The gene expression of CD80 and the frequency of CD86 expression in macrophages was increased. The gene expression of CD206 and the frequency of CD163 expression in macrophages was decreased. SCFA-A upregulated gene expression of IFNG and NOS2 in M1 macrophages.

Conclusions: SCFA- A activated T cells and M1 macrophages, and showed a direct growth inhibitory effect on T3M-1 cells. These finding may support the development of novel cancer therapies that improve the response rate.